ES2909998T3 - Método para establecer, restablecer y preservar la homeostasis de la superficie ocular - Google Patents

Método para establecer, restablecer y preservar la homeostasis de la superficie ocular Download PDF

Info

Publication number
ES2909998T3
ES2909998T3 ES17817868T ES17817868T ES2909998T3 ES 2909998 T3 ES2909998 T3 ES 2909998T3 ES 17817868 T ES17817868 T ES 17817868T ES 17817868 T ES17817868 T ES 17817868T ES 2909998 T3 ES2909998 T3 ES 2909998T3
Authority
ES
Spain
Prior art keywords
eye
fluid
ocular surface
acid
inflammation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES17817868T
Other languages
English (en)
Spanish (es)
Inventor
Wolfgang Georg Konrad Muller-Lierheim
Setten Gysbert-Botho Van
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ICom Medical GmbH
I Com Medical GmbH
Original Assignee
ICom Medical GmbH
I Com Medical GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60766004&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2909998(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ICom Medical GmbH, I Com Medical GmbH filed Critical ICom Medical GmbH
Application granted granted Critical
Publication of ES2909998T3 publication Critical patent/ES2909998T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
ES17817868T 2016-10-14 2017-10-02 Método para establecer, restablecer y preservar la homeostasis de la superficie ocular Active ES2909998T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662408559P 2016-10-14 2016-10-14
US201762516911P 2017-06-08 2017-06-08
PCT/IB2017/001364 WO2018069763A1 (en) 2016-10-14 2017-10-02 Method for establishing, restoring, and preserving homeostasis of the ocular surface

Publications (1)

Publication Number Publication Date
ES2909998T3 true ES2909998T3 (es) 2022-05-11

Family

ID=60766004

Family Applications (1)

Application Number Title Priority Date Filing Date
ES17817868T Active ES2909998T3 (es) 2016-10-14 2017-10-02 Método para establecer, restablecer y preservar la homeostasis de la superficie ocular

Country Status (8)

Country Link
US (1) US20190240251A1 (cg-RX-API-DMAC7.html)
EP (2) EP3525799B1 (cg-RX-API-DMAC7.html)
JP (3) JP2019532105A (cg-RX-API-DMAC7.html)
KR (1) KR20190068575A (cg-RX-API-DMAC7.html)
ES (1) ES2909998T3 (cg-RX-API-DMAC7.html)
HU (1) HUE058672T2 (cg-RX-API-DMAC7.html)
PL (1) PL3525799T3 (cg-RX-API-DMAC7.html)
WO (1) WO2018069763A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE058672T2 (hu) 2016-10-14 2022-09-28 I Com Medical Gmbh Eljárás a szemfelület homeosztázisának megállapítására, helyreállítására és megõrzésére
WO2019202017A1 (en) * 2018-04-18 2019-10-24 i.com medical GmbH High molecular weight hyaluronic acid for treatment and prevention of severe ocular surface disease
EP3852725A4 (en) * 2018-09-20 2022-08-03 The Hong Kong University of Science and Technology EYE DROP COMPOSITIONS
US12268706B2 (en) 2019-01-31 2025-04-08 i.com medical GmbH Hyaluronic acid for relief of idiopathic ocular pain
CN116096355A (zh) * 2020-06-12 2023-05-09 I.Com医疗有限责任公司 用于治疗角膜神经损伤或损失的高分子量透明质酸
CN115989021A (zh) * 2020-06-21 2023-04-18 I.Com医疗有限责任公司 用于治疗和预防高眼压症和青光眼的基于透明质酸的制剂
JP2025524369A (ja) * 2022-06-08 2025-07-30 ザ スケペンス アイ リサーチ インスティテュート，インコーポレイテッド ドライアイ疾患を処置するための方法
EP4591860A1 (en) * 2024-01-23 2025-07-30 FB Vision S.p.A. Ophthalmic pharmaceutical composition for the prevention and treatment of dry eye syndrome

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1263606A (en) * 1985-05-29 1989-12-05 Jeffrey P. Gilbard Non-toxic opthalmic preparations
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
JP3050898B2 (ja) * 1990-07-06 2000-06-12 千寿製薬株式会社 水性医薬製剤
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
IT1277707B1 (it) * 1995-12-22 1997-11-11 Chemedica Sa Formulazione oftalmica a base di ialuronato di sodio per uso nella chirurgia oculare
SE9700827D0 (sv) * 1997-03-07 1997-03-07 Pharmacia & Upjohn Ab Ophthalmic composition
TR200302105T4 (tr) * 2000-04-07 2004-02-23 Laboratoire Medidom S. A. Siklosporin, hiyalüronik asit ve polisorbat içeren göz formülasyonları.
US6528464B1 (en) * 2001-08-17 2003-03-04 Bausch & Lomb Incorporated Composition and method for inhibiting uptake of biguanide antimicrobials by hydrogels
JP3779200B2 (ja) * 2001-11-28 2006-05-24 電気化学工業株式会社 ヒアルロン酸及び／又はその塩の水溶液の安定化組成物
DE10161149B4 (de) * 2001-12-12 2007-03-08 Ursapharm Arzneimittel Gmbh & Co. Kg Verwendung von Heparin-haltigem Ophthalmikum
CN103638040A (zh) * 2002-07-03 2014-03-19 派瑞克科学公司 透明质酸组合物以及使用方法
DE10360425A1 (de) 2003-12-19 2005-07-28 Ursapharm Arzneimittel Gmbh & Co. Kg Verwendung von Hyaluronsäure, Hyaluronat und/oder deren Derivate zur Herstellung einer pharmazeutischen Zusammensetzung
EP1942912B1 (en) * 2005-10-12 2016-12-14 Seikagaku Corporation Agent for applying to mucosa and method for production thereof
JP2008255061A (ja) * 2007-04-06 2008-10-23 Shiseido Co Ltd 可溶性架橋ヒアルロン酸含有眼用組成物
WO2009025763A2 (en) * 2007-08-16 2009-02-26 Schepens Eye Research Institute Therapeutic compositions for treatment of inflammation of ocular and adnexal tissues
RU2015129822A (ru) * 2008-05-15 2015-11-10 Р-Тек Уено, Лтд. Фармацевтическая композиция для лечения сухости глаз и/или повреждения конъюнктивы и роговицы
JP5595206B2 (ja) * 2009-09-30 2014-09-24 ロート製薬株式会社 眼科用液体組成物
US8283463B2 (en) * 2010-02-09 2012-10-09 Bausch & Lomb Incorporated Sterile hyaluronic acid solutions
LT2598526T (lt) * 2010-07-29 2018-10-10 Eleven Biotherapeutics, Inc. Chimeriniai il-1 receptoriaus i tipo agonistai ir antagonistai
KR20170018462A (ko) * 2010-09-10 2017-02-17 산텐 세이야꾸 가부시키가이샤 Ｐ2ｙ2 수용체 작동약 및 히알루론산 또는 그 염을 조합한 것을 특징으로 하는 드라이 아이 치료제, 드라이 아이의 치료 방법, 및 그 용도
KR20170100483A (ko) * 2014-12-02 2017-09-04 리제너론 파마슈티칼스 인코포레이티드 건성안을 위한 동물 모델 및 이러한 동물의 이용 방법
SG10201901426WA (en) * 2015-03-06 2019-03-28 Santen Pharmaceutical Co Ltd Ophthalmic composition
US20170014339A1 (en) 2015-07-17 2017-01-19 i.com medical GmbH Tear Substitute, Fluid for Being Used as a Tear Substitute, and Method for Producing a Tear Substitute
HUE058672T2 (hu) 2016-10-14 2022-09-28 I Com Medical Gmbh Eljárás a szemfelület homeosztázisának megállapítására, helyreállítására és megõrzésére
WO2019202017A1 (en) * 2018-04-18 2019-10-24 i.com medical GmbH High molecular weight hyaluronic acid for treatment and prevention of severe ocular surface disease
US12268706B2 (en) * 2019-01-31 2025-04-08 i.com medical GmbH Hyaluronic acid for relief of idiopathic ocular pain

Also Published As

Publication number Publication date
WO2018069763A1 (en) 2018-04-19
EP3871682A1 (en) 2021-09-01
US20190240251A1 (en) 2019-08-08
PL3525799T3 (pl) 2022-05-16
JP2022153583A (ja) 2022-10-12
EP3525799A1 (en) 2019-08-21
JP2025029084A (ja) 2025-03-05
EP3525799B1 (en) 2022-01-26
HUE058672T2 (hu) 2022-09-28
JP2019532105A (ja) 2019-11-07
KR20190068575A (ko) 2019-06-18

Similar Documents

Publication Publication Date Title
ES2909998T3 (es) Método para establecer, restablecer y preservar la homeostasis de la superficie ocular
US20250276004A1 (en) High molecular weight hyaluronic acid for treatment and prevention of severe ocular surface disease
JP2020502197A (ja) ドライアイ疾患の治療のための眼科用組成物
CA3097470A1 (en) High molecular weight hyaluronic acid for enhancing epithelial survival and reconstitution of body surfaces
JP2008543877A (ja) Ｌｋｋｔｅｔおよび／またはｌｋｋｔｎｔ組成物および組織の悪化、傷害または損傷を処置または予防するための方法
ES3008008T3 (en) Use of high molecular weight hyaluronic acid as ocular transporting vehicle
US12268706B2 (en) Hyaluronic acid for relief of idiopathic ocular pain
US20230241096A1 (en) High molecular weight hyaluronic acid for use in the treatment of corneal nerve damage or loss
RU2679319C1 (ru) Гелеобразная искусственная слеза с антисептическим и репаративным действием
EA046057B1 (ru) Высокомолекулярная гиалуроновая кислота для лечения и предупреждения тяжелого заболевания глазной поверхности
EA050162B1 (ru) Высокомолекулярная гиалуроновая кислота для улучшения выживания эпителия и восстановления поверхностей тела
EP3634416B1 (en) Methods and compositions for reducing corneal endothelial cell loss
Karabulut et al. Changes of Tears MCP-1 Level After External Dacryocystorhinostomy in Primary Acquired Nasolacrimal Duct Obstruction